M.Al Ghobain, F. Rebh, A. Saad, A.H. Khan, N. Mehyar, A. Mashhour, . . . M.Al Jeraisy. (2022). The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial). Elsevier.
Chicago Style (17th ed.) CitationM.Al Ghobain, et al. The Efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with Moderate COVID-19 Pneumonia (pilot Randomized Clinical Trial). Elsevier, 2022.
MLA (9th ed.) CitationM.Al Ghobain, et al. The Efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with Moderate COVID-19 Pneumonia (pilot Randomized Clinical Trial). Elsevier, 2022.
Warning: These citations may not always be 100% accurate.